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SMURF   SMAD ubiquitin regulatory factors 
SARA smad anchor for receptor activation 
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GO  gene ontology  
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This thesis is based on the following articles, which will be referred to in the text by their 
Roman numerals: 
I Johannes 
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Alterations in circulating activin A, GDF-15, TGF-beta3 and MMP-2, -3, and -9 during 
one year of left ventricular reverse remodelling in patients operated for severe aortic 
stenosis. Eur J Heart Fail 2008;10:1201-1207. 
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 Non-invasive evaluation of a mouse model of reverse cardiac remodelling 
following banding-debanding of the ascending aorta. Submitted.  
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%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%%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Inhibition of SMAD2 phosphorylation preserves cardiac function during pressure 
overload. Submitted. 
IV /3*%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!"&!"9$%()9!"$7#,#6"3*77!*5#$
*7%!",9&!7!$"$%:!#%"%#*#%%"	*%#	%%
Collagen  isoform  shift  during  the  early  phase  of  reverse  left  ventricular  
remodelling  after  relief  of  pressure  overload. Eur Heart J 2010, in press. 
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	;	 
Aortic stenosis is the most common aetiology for aortic valve replacement (1). Calcification 
of the valve is the usual aetiology (2) leading to stiffening of the leaflets and gradually 
increased constriction usually developing over decades. Pressure overload leads to left 
ventricular remodelling, typically with development of concentric hypertrophy. The initial 
phase of remodelling is considered to be a beneficial and compensatory process reducing 
wall-stress. Ultrastructurally there is hypertrophy of cardiomyocytes and increased 
myocardial fibrosis (3). A gene shift with increased expression of fetal genes such as 
-
-!"-#
place (4-7). Subsequently myocardial remodelling leads to reduced cardiac function (8) and 
eventually the patient develops clinical symptoms, which classically is angina, syncope or 
heart failure (9). In the later years also subtle symptoms, such as increased fatigability, have 
been recognized as symptoms of aortic stenosis (10). Unless operated, the prognosis after 
onset of symptoms is poor (Figure 1).  
In aortic stenosis, a limited coronary vasodilator reserve in addition to increased left 
ventricular muscle mass may reduce the coronary blood flow per gram of muscle. This may 
cause subendocardial ischemia during increased cardiac work causing angina pectoris even 
#)+%< The natural history of aortic stenosis. The prognosis is poor following the onset of 
symptoms. Modified after Ross J, Jr., Braunwald E. Aortic stenosis. Circulation 1968. 
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in the absence of coronary artery disease (2). 
Operative results for aortic valve replacement have improved over the years and mortality 
rates have declined to about 2% (11). The native aortic valve is replaced either by a 
mechanical valve or a biological valve prosthesis. While limited durability is the main concern 
for biological valves, the mechanical valves requires anticoagulation to avoid 
thromboembolic events. Although knowledge about myocardial remodelling is increasing, 
there are several crucial gaps in our understanding of this process, such as what causes the 
transition from compensated hypertrophy to overt heart failure and how the myocardial 
remodelling process is regulated. Correction of the increased afterload in aortic stenosis by 
aortic valve replacement leads to a process known as reverse remodelling. Left ventricular 
mass is usually normalized after 18 months (12, 13), while regression of fibrosis may take 
more than five years (14). There is limited knowledge regarding how the reverse remodelling 
process is regulated. 
The heart may respond to hemodynamic stress by secreting different mediators (15, 16). 
Several growth factors and cytokines contribute to myocardial remodelling and may 
contribute to cardiac dysfunction (17) and a role for members of the TGF-$&
been suggested (7, 18-22). The TGF-$&$&
several important biological processes, such as cell proliferation and differentiation in 
different tissues (vessels, skin), during embryonic development and in pathological processes 
such as fibrosis and cancer (23).  
The SMAD (small mothers against decapentaplegic) proteins are transcription factors that 
are activated by different TGF-$&'*! pathways are 
SMAD2/3 which is activated by TGF-+<=>?>@'
bone morphogenic protein (BMP) (Figure 2). Upon ligand stimulation TGF-&&
and II form a complex leading to phosphorylation of SMADs. There are seven different type I 
receptors, activin like kinase (ALK) 1-7, with affinity to different SMADs. The SMADs form a 
complex with co-SMAD4, which translocates to the nucleus and regulates transcription 
(Figure 2) (24). There are two inhibitory SMADs, SMAD7 inhibits SMAD2/3 and SMAD6 
inhibits SMAD1/5/8 (25). In addition there are interactions with different proteins, such as 
SMURF (SMAD ubiquitin regulatory factors) and SARA (Smad Anchor for Receptor Activation) 
(26). There is strong reason to believe that the TGF-$&&
disease (25). 
The extracellular matrix (ECM) provides support and anchorage for cells. Collagen is an 
important ECM protein in the heart and is a major determinant of myocardial stiffness (27, 
28). In addition to collagen, the ECM is composed of elastin, proteoglycans, hyaluronic acid, 
fibronectin and laminin. The ECM has been recognized to be more than an inert micro-  
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skeleton, as there are important interactions with the cells, e.g. acting as a reservoir for 
growth factors (29). Mature collagen is made up of three polypeptide strands that are 
twisted and coiled into a triple-helix. There are fibrillar and non-fibrillar collagens. Type I, II, 
Figure 2. The SMAD signalling system. Modified after Schmierer B, Hill CS. TGFbeta-
SMAD signal transduction: molecular specificity and functional flexibility. Nat Rev Mol 
Cell Biol 2007. 
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III, V and XI are fibrillar collagens (30). Type IV is important in the basal lamina (31). Type I 
and III are the most abundant collagens in the adult heart (32).  Type I is also abundant in the 
Achilles tendon, it forms long fibers and provides tensile strength (33, 34). Extensile 
properties have been attributed to collagen type III, which is found in arteries and the uterus 
(35-37). Collagen VIII may form hexagonal networks (38). A total of 29 different collagen 
types have been identified so far.  Also important for the ECM are the matrix 
metalloproteinases (MMPs) and their tissue inhibitors (TIMPs). The MMPs are a group of 
zinc-dependent endopeptidases, which are capable of degrading ECM proteins including the 
collagens. There are four different TIMPs that act as key regulatory proteins by inhibiting 
MMP activity. There is increasing evidence that ECM changes are important in myocardial 
remodelling and that the MMPs and TIMPs have an important role in regulating ECM 
constitution (39). 
The myocardial remodelling process has been addressed in numerous studies, however, 
whether TGF->+<signalling is beneficial or deleterious still remain to be resolved (40, 
41). Furthermore, our knowledge about the reverse remodelling process taking place after 
correction of pressure overload, such as following aortic valve replacement for aortic 
stenosis, is limited. Thus, aortic stenosis is a common, serious disease leading to detrimental 
myocardial remodelling. Results from operative treatment are good, however extensive 
preoperative remodelling implies increased operative risk (42). Extensive remodelling may 
also cause persisting long-term cardiac dysfunction and incomplete reverse remodelling is 
associated with persisting cardiac dysfunction (12). Even though knowledge regarding the 
involvement of different mediators in myocardial remodelling is increasing, there are still 
gaps in our understanding of how the myocardial remodelling process is regulated. The 
reverse remodelling process has been less studied and we do not know whether there are 
mediators regulating this process. The TGF-$&&
myocardial remodelling, however it has not been studied if the TGF-$&&
role in the regulation of reverse remodelling.  
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The main aim of this thesis was to study the TGF-$&[\+$
and experimental aortic stenosis and during reverse remodelling following surgical 
correction of pressure overload. 
 
PAPER I:  
We wanted in paper I to examine plasma levels of activin A, GDF-15 and TGF-]
and serum levels of MMP-2, MMP-3 and MMP-9 before and after aortic valve 
replacement for aortic stenosis. We furthermore wanted to correlate mediator 
levels to parameters of physical performance and left ventricular remodelling.  
 
PAPER II:  
The aim in paper II was to establish a hemodynamically well characterized 
mouse model of reversible left ventricular pressure overload by banding and 
subsequent debanding of the ascending aorta. 
 
PAPER III: 
In paper III we aimed to determine the role of SMAD2/3 signalling on myocardial 
remodelling and cardiac function following pressure overload using a 
pharmacological inhibitor of SMAD2/3 signalling in a mouse model of aortic 
banding. 
 
PAPER IV: 
In paper IV we wanted to examine alterations in myocardial gene expression 
and subsequently to identify molecular alterations important for the early phase 
of reverse remodelling following correction of pressure overload in a mouse 
model. 
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	,	 
ANIMAL MODELS 
Although there are obvious major phenotype differences, such as size, tail, ears, fur and 
bilateral venae cavae superior, 99% of mouse genes have a detectable human homolog (43). 
There are also physiological differences, e.g. basal heart rate which is about 600-700 bpm in 
mice (44) and 60-70 bpm in man. Mice, however, are attractive for comparative medical 
research as mice are small, affordable and do not require much space in comparison with 
larger animals such as the pig. The mouse genome has been sequenced and transgenic and 
knock-out techniques have been developed (43). In addition most lab mice are inbred which 
reduces inter-individual variability, and in particular genetic variability, making mice the 
current ideal species for lab studies of gene expression (45). In the later years there have 
been several advances in surgical mouse models, such as aortic banding inducing left 
ventricular pressure overload mimicking aortic stenosis and hypertension, as well as in 
refinement of anaesthetic techniques (46). The development of methods for hemodynamic 
evaluation in mice, such as echocardiography, pressure-volume catheters and cardiac 
magnetic resonance imaging, has also been impressive (44). However, to be able to transfer 
scientific discoveries in mice models to knowledge in human medicine, the findings should at 
least be supported by observations in patients.  We have established a banding-debanding 
#)+%=Reverse remodeling was induced in mice by banding and subsequent debanding 
of the ascending aorta. Modified after Tarnavski O. Mouse surgical models in 
cardiovascular research. Methods Mol Biol 2009. 
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model, in which mice are subjected to four weeks of banding of the ascending aorta, 
followed by a debanding operation (Figure 3). 
 
ECHOCARDIOGRAPHY 
Mouse echocardiography represents a great advance in the field of comparative cardiac 
research as it allows for in vivo non-invasive measurements of cardiac structure and 
function. The opportunity to perform repeated measurements in the same individual is an 
additional benefit. Spatial and temporal resolution is steadily improving and more refined 
techniques, such as tissue Doppler imaging and strain echocardiography have been 
developed. However, there are several concerns to be addressed in mouse 
echocardiography. The collection of echocardiographic recordings is a delicate skill (47) and 
all recordings in this thesis have been performed by one operator. The operator must be 
unbiased and should preferably be blinded from treatment groups. If echocardiography is to 
be preformed in wake animals the animals should be acclimatized to the examination 
situation by daily training to reduce stress. If animals are sedated care should be taken to 
avoid deep sedation as this leads to cardiodepression. The level of sedation should also be 
carefully standardized to avoid excess variability that might mask important findings. 
Anesthetized mice rapidly lose body heat and hypothermia reduces cardiac function, thus, a 
heat source should be used and body temperature should preferably be monitored. A swift 
recording procedure by a trained operator enhances the quality of data from mouse 
echocardiography.  
Most of these concerns are not valid for echocardiography in human patients, as this 
examination usually is performed while the patients are awake, the human heart is larger 
and the heart rate is slower which allows for better resolution. However standardized 
recordings and measurements performed by an unbiased and experienced 
echocardiographer is critical for good data quality and the examiner should preferably be 
blinded to patient details. 
 
MICROARRAY SCREENING 
Microarray screening is a recent technological development which allows for simultaneous 
analysis of expression of multiple genes. Affymetrix GeneChip analyses over 39.000 
transcripts on one single array. The processing of microarray data has also been refined and 
open source software is shared in the scientific community through BioConductor 
(http://www.bioconductor.org/). Bioinformatics’ software, such as topGO, allows for elegant 
analyses and interpretation of microarray data. Biological function can be difficult to 
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understand from regulation of single genes and by using a refined bioinformatics algorithm 
TopGO scores functional gene ontology (GO) groups taking local dependencies between GO 
terms into account (48). The substantial amount of data generated from microarray 
screening, however, may be confusing and difficult to interpret. The large number of 
analyses also represents a statistical concern, as a level of significance of p = 0.05 just by 
chance would generate 5 positive tests out of 100 performed. Thus, 39.000 tests would by 
chance generate 1950 positive tests. There are statistical methods to correct for multiple 
testing, such as the Bonferroni correction. However, a rigid method to correct for multiple 
testing will disguise potential important findings in such a screening. False discovery rate 
(FDR) is the expected rate of false positive results in an analysis of multiple genes and 
statistical methods to estimate FDR have been developed and represent important tools in 
the analysis of microarray data (49). We have therefore collaborated closely with statistical 
experts in the field of bioinformatics’. The cost of gene chips is rather high, which usually 
leads to a rather small number of animals included in microarray studies. Important findings 
must be verified either on the transcriptional level (e.g. by QPCR) or by protein analyses (see 
below). 
 
QUANTITATIVE REAL TIME POLYMERASE CHAIN REACTION 
Quantitative real time polymerase chain reaction (QPCR) is a method to analyze expression 
of individual genes, by determining levels of mRNA with a particular genetic sequence in a 
specimen (50-52). This technique is now widely used to quantify mRNA. Following mRNA 
isolation reverse transcriptase is used to create complimentary DNA (cDNA), as mRNA is an 
unstable molecule. On sacrifice of the animal, care should be taken to snap freeze tissue in 
liquid nitrogen (-80°C) without delay, as mRNA degradation may introduce variability in the 
data from QPCR analyses that might be avoided. cDNA is amplified by reaction with a 
fluorescent reporter and measured in a thermocycler. The cycle at which the fluorescence 
crosses the threshold is determined and this corresponds to the level of the mRNA level in 
the specimen. A small amount of tissue yields sufficient mRNA to perform multiple QPCR 
analyses. QPCR is a sensitive method to detect transcriptional alterations. As it is less 
laborious than, for example, Western blot, QPCR is an attractive method for verifying 
microarray findings. 
 
WESTERN BLOTTING 
While an analysis of gene expression may be used as a marker of protein synthesis, Western 
blot (immunoblot) is an analytic technique to determine protein levels (53, 54). Briefly, 
proteins are isolated from tissue specimens, separated by size using gel electrophoresis, 
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transferred to a membrane and detected using specific antibodies, visualized by 
chemiluminescence and quantified by densitometry. Protein loading may be controlled by 
Commassie Blue staining. Antibody qualities are most important if false negative and false 
positive results are to be avoided. Another limitation is the number of lanes in each gel (15 
in our lab). We have in our experiments used a reference group (sham aortic banding mice 
fed standard chow) in each gel which makes it possible to make comparisons across multiple 
gels. 
 
ENZYME-LINKED IMMUNOSORBENT ASSAY  
Enzyme-linked immunosorbent assay (ELISA) is another technique for protein analyses (55, 
56). We have used commercial kits using the “sandwich ELISA” technique. Briefly the kit 
contains a microplate pre-coated with antibody specific for the protein to be analyzed. 
Standards and samples are applied and unbound substances are washed away. An enzyme 
linked protein specific antibody is added to the wells, the plate is washed and a solution with 
a chemical being converted to colour by the enzyme is applied. The intensity of the colour is 
measured. The intensity of each sample is related to the standard curve which gives the 
concentration of the protein of interest in the specimens. Antibody specificity is of course 
important also in this technique. 
 
MULTIPLEX 
A multiplex protein assay allows for simultaneous examination of multiple proteins in a 
sample (57, 58). This is particularly useful when the biological sample is of limited amount. 
The technology is based on a family of fluorescently dyed microspheres, or beads, from 
Luminex Corp., the use of a special flow cytometer to measure the reactions occurring on 
the surface of the microspheres and a high-speed digital signal processor to manage the 
fluorescent output. Antibody specificity is of high importance in this technique. While 
proteins are separated by size in Western blot, this is not the case with multiplex and ELISA 
analyses, thus antibody specificity is even more important for both these techniques than for 
Western blot. 
 
HIGH PRESSURE LIQUID CHROMATOGRAPHY 
High pressure liquid chromatography (HPLC) is a biochemical technique to quantify the 
concentration of different molecules (59). Briefly the sample to be analyzed passes through 
a column and the analyte is slowed from physical and chemical interaction with the column. 
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Thus, the time it takes a particular analyte to pass through the column is a fairly specific 
property of the substance to be quantified. Finally, the analyte is detected by fluorescence. 
 
CALCIUM TRANSIENTS 
Cardiomyocytes were isolated from the excised heart (60). Briefly, the heart was perfused 
with collagenase in a Langendorff setup. Collagenase breaks down collagen, which is a key 
component in the extracellular matrix. A biopsy was minced and gently shaken in a solution, 
filtrated and sedimented. The isolated cells were then washed from the enzyme solution. 
Aortic cannulation can be challenging in mice subjected to ascending aortic banding and care 
should be taken during the banding operation to place the ligature cranially on the 
ascending aorta. Myocytes were plated in an open-perfusion chamber mounted on the stage 
of an inverted microscope, labeled with fluo-4 AM and perfused with Hepes Tyrode’s 
solution. Ca2+
 
 transients were calculated from whole cell fluorescence recorded during field 
stimulation at 1 Hz under a mercury lamp (60-62). Isolated cardiomyocytes are sensitive to 
temperature and care must be taken to maintain ambient temperature at 37 °C during the 
experiments.  
CARDIOMYOCYTE CULTURE 
Cardiomyocytes were isolated from neonatal Wistar rats (1-3 days old) (63). Briefly, hearts 
were cut into small pieces and digested with collagenase and pancreatin. To separate 
cardiomyocytes from non-cardiomyocytes, the cell suspension was centrifuged through a 
discontinuous Percoll gradient. Cardiomyocytes were allowed to attach to culture dishes 
overnight in plating medium. Stimulation with TGF-=+=`{|
of serum starvation. Cells need stable conditions both with respect to temperature (37 °C) 
and medium. 
 
PHARMACOLOGIC INHIBITION BY SM16 
SM16 is a novel small molecule inhibitor of TGF-&&$
provided by Dr. Leona Ling at Biogen Idec (64). In vitro efficacy of SM16 has been tested in 
cultured human liver carcinoma cells (HepG2) (64) and murine AB12 tumor cells (65) and 
inhibition of SMAD2 phosphorylation has been demonstrated at 620 nmol/L. Its specificity 
has been tested against 60 different kinases and SM16 effectively inhibits ALK 5 and ALK4, 
without effect on ALK1 or ALK6. Weak inhibitory effect has been demonstrated against 
P38/SAPK2a and Raf. Routes of administration and in vivo dose-response have been 
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determined in BALB/C mice and efficacy of orally administrated SM16 was excellent (65). 
SM16 formulated into murine chow at a dose of 0.45g SM16/kg chow led to a plasma 
concentration of 6.7±2.4 μmol/L (Figure 4). Plasma levels were determined in blood samples 
from a.m. and p.m. time-points without significant differences being described (65). At 0.25, 
0.45 and 0.65 g SM16/kg chow no toxic effects were observed, but at the highest dose (1.7 g 
SM16/kg chow) the animals suffered from weight loss and ill-looking appearance most likely 
demonstrating a toxic effect at high doses. Thus, we were recommended the dose of 0.45 g 
SM16/kg chow by our collaborator at Biogen Idec.  
 
STATISTICS 
Data are presented as mean±standard error of the mean (SEM). Data not normally 
distributed were logarithmically transformed. Parametric statistics were used where data 
conformed to the assumptions of normality and non-parametric statistics when this criterion 
was not fulfilled. In paper I and for echocardiographic measurements in paper IV one way 
repeated measures ANOVA, Friedman Repeated Measures ANOVA on Ranks, two-sided 
paired t-test or Wilcoxon Signed Rank Test was used to analyze repeated measurements 
from the same individual. When comparing two different groups two-sided Student’s t-test, 
Welch t-test or Mann–Whitney Rank Sum Test was used. In paper III, data were analyzed by 
standard two-way ANOVA, as this takes into account the two different interventions in this 
model (pressure overload and SM16 treatment). In paper IV, we employed an ANOVA model 
for each gene that was programmed in R-script. This allowed for identification of the effects 
#)+%> In vivo dose response of SM16 in mice. Modified after Suzuki E et al. A novel 
small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) 
inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after 
surgical resection. Cancer Res 2007. Afternoon (PM), early morning (AM). 
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of correcting pressure overload, taking into account the effects of surgical trauma and 
pressure overload itself. The relation between two continuous variables was examined by 
linear regression. Multiple comparisons were corrected for by Dunn's test for non-
parametric and the Holm–Sidak method for parametric tests. For microarray data multiple 
comparisons were corrected for by using FDR according to Benjamini & Hochberg (49). We 
used p*?*!\&$
SigmaPlot was used for the analyses.  
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PAPER I: 
;?;	 
Twenty-two patients undergoing aortic valve replacement for aortic stenosis were examined 
by echocardiography and a six minute walking test preoperatively, 2 days, 6 and 12 months 
postoperatively. Plasma levels of activin A, growth differentiation factor-15 (GDF-15) and 
TGF-]$++-2, -3 and -9 were analyzed by ELISA. Preoperatively the 
average peak valvular gradient was 89.3±4.8 mmHg, indicating severe aortic stenosis. Aortic 
valve replacement induces reverse remodelling and left ventricular mass was reduced from 
198±14 g/m2 preoperatively to 120±7 g/m2 after 12 months. Left ventricular ejection fraction 
was normal and was unaltered in this study, however, there was a reduction in NYHA class 
from 2.3 to 1.3, and six minutes walking test was increased from 384±18 to 408±15 m, 
indicating improved physical capacity. Activin A was increased in patients with aortic 
stenosis compared to healthy controls, increasing further at 6 and 12 months following 
aortic valve replacement and was associated with reduced physical performance (Figure 5). 
GDF-15, MMP-3 and -9, for which effects on fibrosis and hypertrophy have been reported, 
were increased 2 days postoperatively.  MMP-3 correlated positively to left ventricular end 
diastolic diameter at 6 and 12 months postoperatively (R = 0.64 and 0.51, respectively). GDF-
15 correlated positively to MMP-3 preoperatively and 2 days postoperatively (R = 0.43 for 
both).   
#)+%@ Activin A was increased in patients with severe AS and increased further following 
AVR (A). At 12 months postoperatively activin A was higher in patients with residual 
symptoms (B). Data are presented as mean+SEM.  Preoperatively (PREOP); 2 days 
postoperatively (2dPO); 6 months postoperatively (6mPO); 12 months postoperatively 
(12mPO). * p*?[*
 * p=0.001 vs NYHA I, n=22. Adapted from paper I. 
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PAPER II
To be able to study reverse remodelling following correction of pressure overload, we 
wanted to establish a mouse model with reversible left ventricular pressure overload by 
banding and subsequent debanding of the ascending aorta. Furthermore, there was a need 
for careful hemodynamic evaluation and serial analyses of left ventricular mass as a marker 
of myocardial remodelling and reverse remodelling. Paper II describes our banding-
debanding mouse model in detail. We found four weeks banding of the ascending aorta to 
induce concentric left ventricular remodelling, as left ventricular weight was increased by 
59% and left ventricular wall thickness was increased with respect to chamber diameter. On 
average, lung weight was 70% increased. Elevated left ventricular filling pressure was 
suggested by increased left atrial diameter (47), indicative of pulmonary congestion. 
Echocardiography demonstrated reversible myocardial dysfunction as evaluated by systolic 
and diastolic tissue velocities. 
: 
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#)+%A Aortic banding induced concentric left ventricular remodeling, with reverse 
remodeling following debanding (A-B). Lung weight was increased following AB, with 
regression taking place following DB (C). Correlation between left ventricular mass estimated 
by echocardiography and left ventricular weight (D). -Data are presented as mean+SEM.  
* p*?p*?@-28, B: n=5-108, C: n=8-28).  Aortic banding (AB); 
debanding (DB). Adapted from paper II. 
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PAPER III
SMAD2/3 mediates TGF-signalling intracellularly. To study the effects of SMAD2/3 
signalling in pressure overload we used the novel SMAD2/3 inhibitor SM16 in mice subjected 
to aortic banding. Aortic banding led to increased SMAD2 phosphorylation and reduced 
cardiac function, as was demonstrated by pulmonary congestion and echocardiographic 
measurements. SM16 inhibited phosphorylation of SMAD2, improved cardiac function and 
attenuated the fetal gene shift (Figure 7).  Aortic banding induced cardiomyocyte 
hypertrophy, with 38% increased cell width, 11% increased cell length and 58% increased 
cell area, which was inhibited by SM16. After one week of aortic banding myocardial 
collagen protein levels were not increased, hence we were not able to evaluate possible 
effects of SMAD2 on cardiac fibrosis. Left ventricular sarcoplasmic reticulum calcium ATPase 
2 (SERCA2) was reduced following aortic banding, while SM16 treatment preserved the 
levels of this important calcium handling protein. SERCA2 levels correlated inversely to lung 
weight, indicating an association between reduced SERCA2 levels and pulmonary congestion. 
Furthermore, in cardiomyocytes isolated from banded mice, cytosolic Ca
: 
2+
 
 removal was 
enhanced by SM16. A role for TGF->+<signalling in regulating SERCA2 was supported by 
in vitro studies of neonatal rat cardiomyocytes, as TGF-=$&&
SMAD2 led to reduced SERCA2 mRNA expression which was prevented by SM16 (Figure 7).  
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Figure 7. Aortic banding (AB) induced phosphorylation of SMAD2, which was inhibited by 
SM16 (A). SM16 treated animals did not develop increased lung weight following AB (B). 
SERCA2 levels were preserved by SM16 (C). SM16 improved Ca2+ handling by enhancement 
of transient decay (D). TGF-=$$
phosphorylation of SMAD2 which was attenuated by SM16 (E) and reduced SERCA2 mRNA 
expression which was prevented by SM16 (F). C Data show mean relative intensity+SEM 
and representative blots. Sham STD=1. 
 Data show mean+SEM. * p*?† 
p*?!<|-8, B: n=22-40, C: n=9-16).  Representative figure of fluorescence 
intensity (F/F0) by time (n=11-16). Aortic banding (AB); standard chow (STD); SM16 chow 
(SM16).  Data show mean relative intensity+SEM and representativ blot. Data show 
mean relative mRNA expression+SEM. Ctrl+no SM16=1. * p*?† p*?
SM16 (n=4-6). Control (Ctrl); stimulated with TGF-=!"-#timulated with SM16 (SM16). 
Adapted from paper III. 
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PAPER IV
To study the reverse remodelling process, we used a mouse model of reversible pressure 
overload by ascending aortic banding and subsequent debanding, which is described in 
detail in paper II. To avoid possible confounding effects of heart failure, we included in this 
study only mice without signs of pulmonary congestion, as was defined by left atrial 
diameter < 2.2 mm after four weeks of banding. This corresponded to 50% increased lung 
weight with respect to sham and affected approximately 50% of the mice. In addition to 
concentric left ventricular remodelling
--myosin heavy chain mRNA 
expression were 6 to 8-fold increased following aortic banding, supporting significant 
myocardial remodelling. Surgical correction of left ventricular pressure overload induced 
reverse remodelling with a rapid decline in left ventricular mass during the first week after 
debanding. Left ventricular collagen, however, remained increased. A functional analysis of 
the results from microarray screening disclosed that genes related to the extracellular 
matrix, and in particular the collagen genes, were the ones most strongly regulated from 
correction of pressure overload. This finding led us to identify a novel myocardial collagen 
isoform shift during the early phase of reverse remodelling. While total collagen remained 2-
fold increased with respect to sham, there was a change in collagen isoform constitution. 
Following aortic banding collagen type III was most increased, at 3 days after debanding type 
I was increased by 50%, while at 7 days type VIII was increased by 70% (Figure 8). We were 
not able to demonstrate increased cardiac synthesis of activin A, TGF-<"-15 following 
debanding. 
: 
#)+%D While total collagen remained increased (A), there was an isoform shift from type 
III, to type I and VIII (B-D) during the early phase of reverse remodeling. A. Total myocardial 
&>[+*p*?*
(n=9-10). B-D. Western blot of collagen subtypes. Sham AB was set to 1. Data show mean 
relative intensity + SEM and representative blots. * p*?*p*=*?-9). 
Aortic banding (AB); debanding (DB); sham aortic banding (sAB); sham debanding (sDB).  
Adapted from paper IV. 
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In paper I we have identified alterations in activin A and GDF-15 in patients with “reversible 
pressure overload” of the left ventricle undergoing aortic valve replacement for aortic 
stenosis. Activin A, GDF-15 and TGF-+<{>]signalling system and share this 
as an intracellular second messenger. Both deleterious and cardioprotective effects have 
been attributed to this signalling system (19, 25, 66), which in paper III led us to study the 
effects of pharmacological inhibition of SMAD2/3 in left ventricular pressure overload. We 
found that the novel drug SM16 attenuated phosphorylation of SMAD2 and preserved 
cardiac function. We suggest beneficial effects on cardiomyocyte Ca
; 
2+
 
 handling as the 
possible mechanism for this cardioprotective effect. In paper II, to mimic aortic valve 
replacement for aortic stenosis, we have established a mouse model of reversible left 
ventricular pressure overload by aortic banding and subsequent debanding of the ascending 
aorta. In paper IV, we found that the expression of genes regulating the ECM were the ones 
most altered following debanding. This led to the discovery of a novel collagen isoform shift 
during the early phase of reverse remodelling. We were not able, however, to identify 
increased cardiac synthesis of TGF-$&'$remodelling in 
mice. 
COMPARATIVE MEDICINE 
Exploring biological mechanisms in human studies may be difficult. Sampling of myocardial 
tissue is, for obvious ethical reasons, limited to a number of conditions, such as explanted 
hearts, donor hearts and small biopsies obtained during open heart surgery. Animal 
experiments allows for access to myocardial tissue for lab experiments. A number of animal 
models of heart disease have been developed. When designing an experimental study 
several issues should be taken into consideration. Pigs and humans are developmentally 
closely related and experimental studies in pigs have provided extensive physiological 
knowledge. In the later years, however, mice have grown popular in cardiac research. 
Despite obvious phenotype differences between mouse and man, gene homology is 
remarkable. In inbred mice, the genetic variation is extremely limited making this species 
excellent for studies of gene expression (67). The advances in genetically modified mice 
represent a powerful tool for researchers (43). During the last two decades several mouse 
models of human cardiac disease have been developed, among them is aortic banding, 
subjecting the left ventricle to pressure overload mimicking aortic stenosis and hypertension 
(46). Refined methods for hemodynamic evaluation in mice, such as echocardiography, have 
been established (68, 69). Low costs increase the feasibility of mice studies. Caution must be 
taken, however, when transferring the results from mice studies to human medicine and 
results should be supported at least by observational studies in man. 
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TRANSFORMING GROWTH FACTOR-	LING 
The TGF-$&$&signalling proteins involved in several important biologic 
processes (25, 70). TGF->+$&!"-
superfamily members (25, 70). In addition to intracellular SMAD phosphorylation, non-SMAD 
pathways may also be activated (71). TGF-	|?
binding leads to SMAD phosphorylation. There is evidence that this signalling system leads 
to increased collagen synthesis (72-74). Involvement of TGF->+<signalling in cardiac 
disease has been suggested (25, 75) and TGF-&$
attenuated myocardial fibrosis, however, both improved (41) and reduced (40) cardiac 
function have been reported. Kuwahara administered an anti-TGF-'
undergoing suprarenal aortic banding and found reduced myocardial fibrosis and improved 
diastolic function (41). Lucas used a genetically modified mouse strain, with an inducible 
dominant negative mutation of the TGF-receptor type II which was unable to activate SMAD. 
Clear effects on cardiac remodelling were demonstrated as transverse aortic constriction in 
animals with impaired TGF->+<signalling developed left ventricular dilatation and 
reduced interstitial collagen and cardiac dysfunction was suggested (40). In paper I we 
demonstrated increased levels of activin A in patients with aortic stenosis. Following aortic 
valve replacement there was a further increase at 6 and 12 months, which represents an 
intermediate time-point during reverse remodelling, when left ventricular mass usually has 
normalized, but ECM changes persists. In addition there was an early increase of GDF-15 at 2 
days postoperatively. In paper IV, however, we were not able to demonstrate increased 
cardiac synthesis of TGF-$&'$remodelling in mice. Species 
difference might be an explanation. The early changes described in paper I at two days 
postoperatively might be due to the surgical trauma and it is possible that the increased 
levels of activin A might represent an epiphenomenon, unrelated to reverse remodelling of 
the heart. 
 
SMAD2/3 SIGNALLING IN PRESSURE OVERLOAD 
TGF-$$&&+<{>]*<"-15 has been demonstrated 
to have antihypertrophic and cardioprotective effects, possibly mediated by SMAD2/3 
activation (19). SMAD2 activation has been reported in failing human hearts (66). Thus it 
remains unclear whether this signalling system mediates or counteracts cardiac dysfunction. 
SM16 is a small molecule inhibitor of ALK4 and 5 which leads to reduced phosphorylation of 
SMAD2/3. SM16 has been tested against 60 different kinases and except inhibiting ALK5 and 
ALK4, only weak inhibitory activity against P38 and Raf were demonstrated (64). In paper III 
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we have used SM16 to inhibit SMAD phosphorylation in mice subjected to aortic banding. 
We found that phosphorylation of SMAD2 was increased following aortic banding. Neither 
phosphorylation of P38, Raf nor SMAD3 was increased. Phosphorylation of SMAD2 was 
attenuated by SM16 treatment. SM16 preserved cardiac function, as evaluated by 
echocardiography and as the pulmonary congestion seen after aortic banding was abolished. 
Although SM16 led to significant inhibition of collagen gene transcription, myocardial 
collagen protein was not altered after one week of aortic banding. This observation makes 
potential effects on collagen synthesis a less likely explanation for the preservation of 
cardiac function demonstrated in our study. Aortic banding led to reduced left ventricular 
levels of SERCA2 (76, 77), while SM16 attenuated this SERCA2 loss. In studies of isolated 
cardiomyocytes, cells from SM16 treated mice demonstrated a more rapid decline of Ca2+
 
 
transients possibly due to improved SERCA2 function. Moreover, TGF-=$
neonatal rat cardiomyocytes demonstrated increased phosphorylation of SMAD2 and 
downregulation of SERCA2 that was inhibited by SM16. We suggest in paper III that SMAD 
signalling has effects in cardiomyocytes subjected to pressure overload and this finding 
might represent the first step to develop a pharmaceutical strategy to improve cardiac 
function by SMAD2 inhibition. 
REVERSE REMODELING 
Following aortic valve replacement for aortic stenosis, reverse remodelling of the left 
ventricle takes place. Left ventricular mass usually normalizes during the first 18 months 
subsequently followed by regression of fibrosis (14). Incomplete reverse remodelling is 
associated with persisting cardiac dysfunction (12). Knowledge about the reverse 
remodelling process is scarce and we do not know how this process is regulated. In paper IV 
we have studied reverse remodelling of the left ventricle in a mouse model of reversible 
pressure overload, described in detail in paper II. We identified a previously unknown 
collagen isoform shift during the early phase of reverse remodelling, as collagen type I was 
transiently increased by 50% at 3 days followed by a later increase in type III (50%) and VIII 
(70%) at 7 days after debanding. Collagen types I and III have different biomechanical 
properties. They are both fibrillar collagens, type I is the stiffer collagen being the dominant 
collagen in the Achilles tendon, while extensile properties has been attributed to collagen 
type III (33, 35). Collagen type VIII is a non-fibrillar collagen and little is known with respect 
to its biomechanical properties. Collagen type VIII is not normally expressed in the human 
heart, but involvement during embryologic development of the heart has been suggested 
(78). Collagen type VIII has been reported to be involved in tissue repair (79) and a role in 
vascular smooth muscle cell migration and MMP expression has been described (80, 81). We 
suggest that the collagen isoform shift observed during reverse remodelling might be 
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important for the biomechanical properties of the heart and the recovery of cardiac function 
following surgical correction of left ventricular pressure overload. 
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PAPER I: 
; 
We have observed an increase in plasma levels of activin A in patients scheduled for aortic 
valve replacement for aortic stenosis compared to healthy controls. Following aortic valve 
replacement there was a further increase at six and twelve months postoperatively with 
higher levels in symptomatic patients. Two days postoperatively circulating GDF-15, MMP-3 
and -9 were increased and GDF-15 was correlated to MMP-3, which again correlated to left 
ventricular end diastolic diameter. 
 
PAPER II: 
We have established a hemodynamically well characterized mouse model of reversible left 
ventricular pressure overload by banding-debanding of the ascending aorta, inducing reverse 
myocardial remodelling. 
 
PAPER III: 
Pharmacological inhibition of SMAD2 signalling by SM16 during pressure overload in mice 
demonstrated that SM16 preserves cardiac function, possibly via beneficial effects on 
cardiomyocyte Ca2+
 
 handling. Even though collagen mRNA expression was attenuated by 
SM16, myocardial collagen protein levels were not altered after one week of aortic banding. 
PAPER IV: 
Alterations in collagen gene expression were the most evident transcriptional changes 
during the early phase of reverse remodelling in mice. Even though total collagen protein 
remained increased following debanding, there was a subtype change as collagen type I 
increased transiently at 3 days followed by a later increase in type III and VIII at 7 days after 
debanding. We suggest that this collagen subtype shift during the early phase of reverse 
remodelling might be important for the biomechanical properties of the heart and the 
recovery of cardiac function. 
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The myocardial remodelling process seen in aortic stenosis eventually leads to cardiac 
dysfunction. Extensive remodelling may contribute to low cardiac output syndrome 
following aortic valve replacement, for which there is currently no effective treatment 
available. Incomplete reverse remodelling following aortic valve replacement for aortic 
stenosis is associated with persisting symptoms and increased mortality. Increased 
knowledge of the mechanisms regulating myocardial remodelling and cardiac function, such 
as the possible effect of TGF->+<signalling on cardiomyocyte SERCA2 levels and Ca
	 
2+
To gain further knowledge it is the ambition of our research group to do further studies on 
these topics. The possible role of collagen VIII during reverse remodelling is intriguing. Both 
direct mechanical effects and effects from interaction with other proteins in the ECM are 
possible. A collagen VIII knock-out has been developed (82, 83) and is available to our group. 
It is our ambition to use this knock-out mouse to address the possible role of collagen type 
VIII in remodelling and reverse remodelling. 
 
homeostasis, might lead to new pharmacologic strategies in the treatment of heart failure. 
Understanding the reverse remodelling process following correction of left ventricular 
pressure overload might lead to treatments enhancing this process. This may be beneficial if 
reverse remodelling following aortic valve replacement for aortic stenosis is incomplete and 
possibly also for patients with hypertensive heart failure. 
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	 
Page 22, legend figure 6: “A: n=13-108” should have been “A: n=8-28” 
Page 29, line 13: “mice” should have been “mouse” 
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